We are excited to announce our move into a new purpose designed office at Richmond Quarter in East Fremantle, Western Australia. The office will house our management, marketing, data and general administration teams. For information about our services, visit >>> theranostics.com.au.
Theranostics Australia’s A/Prof Nat Lenzo will be presenting on clinical patient experience for Lutetium-177 PSMA therapy at the Eckert & Ziegler and Imaxeon “Symposium on Theranostics”, following the conclusion of the 4th Theranostics World Congress in Melbourne, VIC.
Theranostics Australia’s A/Prof Nat Lenzo has joined the National Imaging Facility (NIF) as a member of their Industry Advisory Panel. NIF is an Australian-wide network of world-class imaging infrastructure that merges cutting-edge imaging technologies with highly specialised expertise from 10 universities and research institutes, along with ANSTO, to develop advanced imaging solutions and drive innovation. The NIF Industry Advisory Panel will provide insight and consultation to NIF to improve strategies for increasing collaboration with national and international commercial parties.
Theranostics Australia is very pleased to announce the formation of “Sydney Theranostics” based at Macquarie Medical Imaging, Ground Floor, Macquarie University Hospital, Sydney, NSW. Gallium-68 imaging, Lutetium-177 and other radionuclide therapies are planned to commence December 2016. For further information, contact Dr Pon Anura via email – email@example.com.
Theranostics Australia’s A/Prof Nat Lenzo will be presenting at the 13th Annual CPD Conference (Integrative Imaging Symposium) in Wagga Wagga, NSW, hosted by the Rural Alliance in Nuclear Scintigraphy (RAINS), Charles Sturt University (CSU) and Macquarie University (MQ). The theme for 2016 is “Image Guided Therapy and Theranostics” with A/Prof Nat Lenzo presenting on Gallium-68/Lutetium-177 octreotate in neuroendocrine tumours, and Gallium-68/Lutetium-177 PSMA in prostate cancer.
Interesting article published by The Australian Financial Review on Lutetium-177 PSMA Therapy for advanced prostate cancer, a treatment currently offered by Theranostics Australia >>> http://bit.ly/2dMpZX3
Theranostics Australia is pleased to announce its selection by IPSEN Pharmaceuticals as an approved investigational site for participation in their clinical trial: “An international multi-center, open-label study to evaluate safety, tolerability, biodistribution, dosimetry and preliminary efficacy of 177Lu-OPS201 for the therapy of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP NETs)”. The trial is expected to commence in November 2016.
Theranostics Australia is pleased to announce an agreement with Oceanic Molecular to utilise their Radiological Council approved facilities at Hollywood Private Hospital for the administration of Radium-223, a treatment for metastatic prostate cancer.